Hemogenyx Pharmaceuticals plc (LSE:HEMO), a London-listed biopharmaceutical company developing treatments for blood diseases, published its half-year report on 28 September 2026 describing a clinical trial that has cleared two important hurdles. The central question is how the company is advancing its lead CAR-T therapy for acute myeloid leukaemia, now that it can escalate dosing in adults and open a children's arm, and what its finances allow.

The company and its pipeline

Hemogenyx's lead product is HG-CT-1, a chimeric antigen receptor T-cell (CAR-T) therapy targeting FLT3 for patients with relapsed or refractory acute myeloid leukaemia (AML). Its Phase I trial site is MD Anderson Cancer Center in the US. The company is also developing CDX, a bi-specific antibody for AML and for conditioning before bone marrow transplants, and its Chimeric Bait Receptor platform, which it says is progressing at a measured pace. Its shares are admitted to the Official List and trade on the London Stock Exchange.

The half-year report

According to the report, three adult patients treated at the initial dose level of HG-CT-1 showed CAR-T cell expansion and reduced blast burden, with no neurotoxicity. The company said the trial is positioned for dose escalation in adults and that the US Food and Drug Administration has cleared initiation of a paediatric Phase I arm. After the period end, a first paediatric patient was identified and screening began. The company submitted its second annual IND report to the FDA in April 2026.

Chairman Marc Feldmann said the period "delivered what it needed to deliver: a trial cleared to escalate in adults and to open in children, a Manufacturing base capable of supporting it, the first binding commercial arrangement for the therapy, and the Capital advance the programme."

Hospital exemption agreements

The "binding commercial arrangement" refers to a definitive agreement signed on 11 August 2026 with Cellin Technologies in Estonia. The report describes a five-year exclusive manufacturing and operational Partnership under the hospital exemption framework, with Revenue sharing on patient treatments, an expected four-month technology transfer and a regulatory review of about 90 days. Hemogenyx keeps intellectual property and development rights outside Estonia. On 29 July 2026, it also signed a letter of intent with Vilnius University Hospital Santaros Klinikos in Lithuania, covering translational studies and point-of-care manufacturing.

Financial position

For the six months to 30 June 2026, the company reported a loss before tax of £6.56 million, up from £5.01 million. Operating costs were £6.48 million, including a non-cash share-based payment charge of £5.54 million; the company said that, excluding share options, operating costs were lower than a year earlier. It raised £5.6 million during the half, including £3.0 million from institutional investors, and ended June with cash of £4.58 million and net Assets of £4.27 million, compared with £1.14 million at 31 December 2025. A total voting rights notice on 30 September 2026 put the share count at 6,896,786.

Risks and points to watch

Results from three patients at the lowest dose are very early, and safety and efficacy at higher doses are unknown. Paediatric recruitment has only just begun. Hospital exemption revenue in Estonia depends on technology transfer, regulatory approval and patient numbers. Cash of £4.58 million at mid-year is modest for a company running clinical trials, so additional funding is likely to be needed, and Warrant exercises have already added shares in 2026. Key milestones include dose-escalation data from MD Anderson in adults, paediatric enrolment and completion of the Estonian technology transfer.

Conclusion

Hemogenyx is advancing its AML CAR-T therapy by moving to higher adult doses and opening a paediatric arm, supported by a first binding hospital exemption deal. Its filings show progress, but clinical outcomes and funding remain the decisive uncertainties.